email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
2491 - 2505
of 3615 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
China Finalizes IPO Listing Rules for Shanghai High-Tech Board
$5.00
Available
I-Mab Starts China Trial of In-licensed Interleukin for Solid Tumors
$5.00
Available
WuXi Biologics Signs $220 Million Bi-Specific Deal with ABL Bio of South Korea
$5.00
Available
3SBio Will Pay $50 Million Upfront for China Rights to Two TLC Products
$5.00
Available
China Strengthens Clinical Trial Approval Rules for Cell and Gene Therapies
$5.00
Available
Aslan Out-Licenses Korean Rights for Oncology Drug in $13 Million Deal
$5.00
Available
Nanjing's NJCTTQ Signs $4 Billion In-Licensing Deal for Bi-Specific Immunotherapies from Abpro
$5.00
Available
Innovent Combines PD-1 with Avastin Biosimilar in China HCC Trial
$5.00
Available
Beijing Surgerii Completes A Round for Next-Gen Robotic Surgery Device
$5.00
Available
Shanghai Henlius' Rituxan Biosimilar is First Biosimilar Approved in China
$5.00
Available
Xynomic Starts Phase III Trial of HDAC Inhibitor in South Korea
$5.00
Available
Solasia Announces China Approvals for Two Cancer Side-Effect Treatments
$5.00
Available
WuXi STA Pharma Forms Drug Delivery Collaboration with BioLingus
$5.00
Available
Happy Life and PPD to Offer China Clinical Trial/Post-Marketing Services
$5.00
Available
Hangzhou Sciwind Completes $29.5 A Round for NASH Treatments
$5.00
Available